Group B streptococcus type II polysaccharide-tetanus toxoid conjugate vaccines
AssigneesThe Brigham and Women's Hospital, Inc., National Research Council of Canada
InventorsHarold J. Jennings, Dennis L. Kasper
Life of this patent
Estimating the term…
Abstract
This invention relates to antigenic conjugate molecules comprising the capsular polysaccharide of Group B streptococcus type II which are covalently linked to protein. This invention also relates to vaccines and methods of immunizing mammals, including humans against infection by Group B streptococcus type II (GBS II). Multivalent vaccines comprising the conjugate molecules of this invention and antigens to other pathogenic bacteria are also claimed.
Claims33
An antigenic conjugate molecule comprising a capsular polysaccharide derived from Group B streptococcus type II and a protein component wherein two or more side chains terminating in sialic acid residues of the polysaccharide component are each linked through a secondary amine bond to protein and wherein the molecular weight of the polysaccharide is at least 5000 daltons.
A method of preparing a conjugate molecule of a capsular polysaccharide of Group B streptococcus type II and a protein comprising
- (a) subjecting the Group B streptococcus type II capsular polysaccharide to periodate oxidation sufficient to introduce an aldehyde group into one or more terminal sialic acid residues linked to the backbone of the polysaccharide;
- (b) coupling the oxidized Group B streptococcus type II capsular polysaccharide to a protein through reductive amination to generate a secondary amine bond between the capsular polysaccharide and the protein.
Dependencies are inferred from the claim text.